1
NR 566 MIDTERM EXAM ADVANCED PHARMACOLOGY
2026/2027 | 2 Latest Versions | Care of Family Complete
Review | A Grade | Pass Guaranteed
[VERSION 1 - 75 QUESTIONS]
[V1-A: Pharmacokinetics & Pharmacodynamics Principles (Q1-12)]
Q1. A 58-year-old patient with liver cirrhosis is prescribed a drug that undergoes
extensive first-pass metabolism. The NP should anticipate which effect?
A. Decreased bioavailability of the oral drug
B. Increased bioavailability of the oral drug
C. No change in drug bioavailability
D. Increased renal clearance of the drug
Correct Answer: B
Rationale: In liver cirrhosis, first-pass metabolism is reduced due to decreased hepatic
blood flow and impaired enzymatic activity, leading to increased bioavailability of oral
drugs that normally undergo extensive first-pass extraction. A is incorrect because first-
pass reduction increases, not decreases, bioavailability. C is incorrect because liver
disease significantly alters first-pass metabolism. D is incorrect because renal clearance
is unrelated to first-pass metabolism.
Q2. A drug has a half-life of 6 hours. Approximately how long will it take to reach
steady-state concentration with once-daily dosing?
,2
A. 6 hours
B. 12 hours
C. 24 hours
D. 30 hours
Correct Answer: D
Rationale: Steady-state concentration is reached after approximately 5 half-lives (5 × 6
hours = 30 hours). A represents one half-life (50% elimination). B represents two half-
lives (75% elimination). C represents four half-lives (93.75% elimination) but is not
sufficient for clinical steady-state.
Q3. Which factor would most significantly increase the volume of distribution (Vd) of a
highly lipophilic drug?
A. Increased plasma protein binding
B. Decreased body fat percentage
C. Increased age with higher body fat
D. Decreased tissue perfusion
Correct Answer: C
Rationale: Lipophilic drugs distribute extensively into adipose tissue; increased body
fat (common in older adults) significantly increases Vd. A is incorrect because increased
protein binding decreases Vd by keeping drug in plasma. B is incorrect because
decreased body fat would reduce Vd for lipophilic drugs. D is incorrect because
decreased perfusion would reduce tissue distribution.
Q4. A patient taking warfarin (highly protein-bound) is started on phenytoin (also
highly protein-bound). What is the primary pharmacokinetic concern?
A. Increased warfarin metabolism by CYP2C9 induction
B. Displacement of warfarin from albumin, increasing free fraction
,3
C. Decreased renal excretion of warfarin
D. Increased absorption of warfarin from the GI tract
Correct Answer: B
Rationale: Phenytoin can displace warfarin from albumin binding sites, transiently
increasing the free (active) fraction of warfarin and risk of bleeding, even before CYP
enzyme induction occurs. A is also true but represents a pharmacodynamic interaction
that develops over days. C and D are not relevant mechanisms for this drug pair.
Q5. A partial agonist at a beta-adrenergic receptor will produce which effect?
A. Greater maximal response than a full agonist
B. A submaximal response even at full receptor occupancy
C. No response unless an antagonist is present
D. Blockade of all receptor-mediated effects
Correct Answer: B
Rationale: A partial agonist has lower intrinsic activity than a full agonist, producing a
submaximal response even when all receptors are occupied. A describes a superagonist.
C describes an inverse agonist. D describes a competitive antagonist.
Q6. A 72-year-old patient with heart failure has reduced cardiac output. How does this
affect the pharmacokinetics of lidocaine administered IV?
A. Increased hepatic clearance due to increased hepatic blood flow
B. Decreased hepatic clearance due to reduced hepatic blood flow
C. Increased renal clearance due to increased GFR
D. No effect on drug clearance
Correct Answer: B
Rationale: Lidocaine has high hepatic extraction ratio (flow-dependent clearance);
reduced cardiac output decreases hepatic blood flow, thereby decreasing lidocaine
, 4
clearance and increasing risk of toxicity. A is opposite of the correct effect. C is incorrect
because reduced cardiac output decreases, not increases, renal perfusion. D is incorrect
because flow-dependent drugs are significantly affected by cardiac output changes.
Q7. Which statement best describes the concept of "therapeutic index"?
A. The ratio of the toxic dose to the effective dose in 50% of the population
B. The dose required to produce toxicity in 95% of patients
C. The ratio of LD50 to ED50
D. The plasma concentration at which 50% of receptors are occupied
Correct Answer: C
Rationale: Therapeutic index is defined as the ratio of the lethal dose in 50% of
subjects (LD50) to the effective dose in 50% of subjects (ED50); a narrow therapeutic
index indicates a small margin of safety. A reverses the ratio. B describes TD95. D
describes the EC50 for receptor occupancy.
Q8. A drug follows zero-order kinetics at high concentrations. Which statement is
correct?
A. A constant fraction of the drug is eliminated per unit time
B. A constant amount of the drug is eliminated per unit time
C. The half-life remains constant regardless of concentration
D. The drug is eliminated primarily by glomerular filtration
Correct Answer: B
Rationale: Zero-order kinetics means a constant amount (not fraction) of drug is
eliminated per unit time, typically occurring when metabolic enzymes are saturated
(e.g., phenytoin, aspirin at high doses, ethanol). A and C describe first-order kinetics. D
is not specific to zero-order kinetics.
NR 566 MIDTERM EXAM ADVANCED PHARMACOLOGY
2026/2027 | 2 Latest Versions | Care of Family Complete
Review | A Grade | Pass Guaranteed
[VERSION 1 - 75 QUESTIONS]
[V1-A: Pharmacokinetics & Pharmacodynamics Principles (Q1-12)]
Q1. A 58-year-old patient with liver cirrhosis is prescribed a drug that undergoes
extensive first-pass metabolism. The NP should anticipate which effect?
A. Decreased bioavailability of the oral drug
B. Increased bioavailability of the oral drug
C. No change in drug bioavailability
D. Increased renal clearance of the drug
Correct Answer: B
Rationale: In liver cirrhosis, first-pass metabolism is reduced due to decreased hepatic
blood flow and impaired enzymatic activity, leading to increased bioavailability of oral
drugs that normally undergo extensive first-pass extraction. A is incorrect because first-
pass reduction increases, not decreases, bioavailability. C is incorrect because liver
disease significantly alters first-pass metabolism. D is incorrect because renal clearance
is unrelated to first-pass metabolism.
Q2. A drug has a half-life of 6 hours. Approximately how long will it take to reach
steady-state concentration with once-daily dosing?
,2
A. 6 hours
B. 12 hours
C. 24 hours
D. 30 hours
Correct Answer: D
Rationale: Steady-state concentration is reached after approximately 5 half-lives (5 × 6
hours = 30 hours). A represents one half-life (50% elimination). B represents two half-
lives (75% elimination). C represents four half-lives (93.75% elimination) but is not
sufficient for clinical steady-state.
Q3. Which factor would most significantly increase the volume of distribution (Vd) of a
highly lipophilic drug?
A. Increased plasma protein binding
B. Decreased body fat percentage
C. Increased age with higher body fat
D. Decreased tissue perfusion
Correct Answer: C
Rationale: Lipophilic drugs distribute extensively into adipose tissue; increased body
fat (common in older adults) significantly increases Vd. A is incorrect because increased
protein binding decreases Vd by keeping drug in plasma. B is incorrect because
decreased body fat would reduce Vd for lipophilic drugs. D is incorrect because
decreased perfusion would reduce tissue distribution.
Q4. A patient taking warfarin (highly protein-bound) is started on phenytoin (also
highly protein-bound). What is the primary pharmacokinetic concern?
A. Increased warfarin metabolism by CYP2C9 induction
B. Displacement of warfarin from albumin, increasing free fraction
,3
C. Decreased renal excretion of warfarin
D. Increased absorption of warfarin from the GI tract
Correct Answer: B
Rationale: Phenytoin can displace warfarin from albumin binding sites, transiently
increasing the free (active) fraction of warfarin and risk of bleeding, even before CYP
enzyme induction occurs. A is also true but represents a pharmacodynamic interaction
that develops over days. C and D are not relevant mechanisms for this drug pair.
Q5. A partial agonist at a beta-adrenergic receptor will produce which effect?
A. Greater maximal response than a full agonist
B. A submaximal response even at full receptor occupancy
C. No response unless an antagonist is present
D. Blockade of all receptor-mediated effects
Correct Answer: B
Rationale: A partial agonist has lower intrinsic activity than a full agonist, producing a
submaximal response even when all receptors are occupied. A describes a superagonist.
C describes an inverse agonist. D describes a competitive antagonist.
Q6. A 72-year-old patient with heart failure has reduced cardiac output. How does this
affect the pharmacokinetics of lidocaine administered IV?
A. Increased hepatic clearance due to increased hepatic blood flow
B. Decreased hepatic clearance due to reduced hepatic blood flow
C. Increased renal clearance due to increased GFR
D. No effect on drug clearance
Correct Answer: B
Rationale: Lidocaine has high hepatic extraction ratio (flow-dependent clearance);
reduced cardiac output decreases hepatic blood flow, thereby decreasing lidocaine
, 4
clearance and increasing risk of toxicity. A is opposite of the correct effect. C is incorrect
because reduced cardiac output decreases, not increases, renal perfusion. D is incorrect
because flow-dependent drugs are significantly affected by cardiac output changes.
Q7. Which statement best describes the concept of "therapeutic index"?
A. The ratio of the toxic dose to the effective dose in 50% of the population
B. The dose required to produce toxicity in 95% of patients
C. The ratio of LD50 to ED50
D. The plasma concentration at which 50% of receptors are occupied
Correct Answer: C
Rationale: Therapeutic index is defined as the ratio of the lethal dose in 50% of
subjects (LD50) to the effective dose in 50% of subjects (ED50); a narrow therapeutic
index indicates a small margin of safety. A reverses the ratio. B describes TD95. D
describes the EC50 for receptor occupancy.
Q8. A drug follows zero-order kinetics at high concentrations. Which statement is
correct?
A. A constant fraction of the drug is eliminated per unit time
B. A constant amount of the drug is eliminated per unit time
C. The half-life remains constant regardless of concentration
D. The drug is eliminated primarily by glomerular filtration
Correct Answer: B
Rationale: Zero-order kinetics means a constant amount (not fraction) of drug is
eliminated per unit time, typically occurring when metabolic enzymes are saturated
(e.g., phenytoin, aspirin at high doses, ethanol). A and C describe first-order kinetics. D
is not specific to zero-order kinetics.
